Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Cardiol Therapeutics Inc. (T:CRDL)

Business Focus: Biotechnology & Medical Research

Oct 25, 2021 07:27 am ET
Cardiol Therapeutics Receives Health Canada Approval for Phase II Clinical Trial of CardiolRx(TM) for Acute Myocarditis
Oakville, Ontario--(Newsfile Corp. - October 25, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce that it has received approval from Health Canada to proceed with the Company's Phase II, multi-center, double-blind, randomized, placebo-controlled trial designed to study the safety and tolerability of CardiolRx™ as well as its impact on myocardial recovery in patients presenting with acute myocarditis. The approval follows the U.S. Food and Drug Administration (FDA) providing clearance to proceed with the Company's Investigational New Drug (IND) application to commence this trial, as announced by the Company on August 24th, 2021.
Oct 18, 2021 07:27 am ET
Cardiol Therapeutics Expands LANCER, a Phase II/III Trial of CardiolRx(TM), into Brazil, Mexico, and Canada
Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease
Sep 16, 2021 07:27 am ET
Cardiol Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
Oakville, Ontario--(Newsfile Corp. - September 16, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, announced today that it will present at the 2021 Cantor Virtual Global Healthcare Conference on September 28, at 8:40 am EDT.
Sep 10, 2021 04:33 pm ET
Cardiol Therapeutics Announces Acceleration of Expiry Date of Warrants Issued on June 4, 2020
Oakville, Ontario--(Newsfile Corp. - September 10, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, announces the acceleration of the expiry date of all outstanding common share purchase warrants (the "Warrants") of the Company that were issued on June 4, 2020, pursuant to a Canadian public offering (the "Offering"). The Warrants bear the CUSIP Number: 14161Y127 and the ISIN: CA14161Y1271. The Warrants are not listed for trading on the TSX or NASDAQ.
Sep 07, 2021 07:27 am ET
Cardiol Therapeutics Appoints Michael J. Willner to Its Board of Directors
Oakville, Ontario--(Newsfile Corp. - September 7, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce the appointment of Michael J. Willner, Esq. to its Board of Directors, effective immediately.
Aug 24, 2021 07:27 am ET
Cardiol Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for Phase II Clinical Trial of CardiolRx(TM) for Acute Myocarditis
Oakville, Ontario--(Newsfile Corp. - August 24, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce that the U.S. Food and Drug Administration (FDA) has provided clearance to proceed with the Company's Investigational New Drug (IND) application to commence a Phase II, multi-center, double-blind, randomized, placebo-controlled trial designed to study the safety and tolerability of CardiolRx™, as well as its impact on myocardial recovery in patients presenting with acute myocarditis.
Aug 09, 2021 07:27 am ET
Cardiol Therapeutics to Commence Trading on NASDAQ Under the Symbol "CRDL"
Oakville, Ontario--(Newsfile Corp. - August 9, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, announced today that it has received final approval from The Nasdaq Capital Market LLC ("NASDAQ") to list its common shares on NASDAQ. The Company's shares will begin trading on August 10, 2021, under the symbol "CRDL".
Jul 07, 2021 07:33 am ET
Cardiol Therapeutics' Board of Directors Appoints Dr. Guillermo Torre-Amione as Chairman
Oakville, Ontario--(Newsfile Corp. - July 7, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, today announced that its Board of Directors has appointed Dr. Guillermo Torre-Amione as the new Chairman. Dr. Torre-Amione has been an independent director of Cardiol since August 2018 and is taking over from Dr. Eldon Smith, who is the founding Chairman of Cardiol and is now retiring from the Board.
Jun 30, 2021 10:03 am ET
Cardiol Therapeutics Reports Results of 2021 Annual General and Special Meeting
Oakville, Ontario--(Newsfile Corp. - June 30, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, announces results from its Annual General and Special Meeting of Shareholders (the "AGM") held virtually via live audio webcast, on June 29, 2021. Shareholders voted in favour of all management resolutions proposed in the Company's Information Circular.
Jun 28, 2021 10:03 am ET
Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting on June 29th at 4:30 p.m. EDT
Oakville, Ontario--(Newsfile Corp. - June 28, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce that the Company's virtual Annual General and Special Meeting of Shareholders (the "AGM") will be webcast on June 29, 2021, at 4:30 p.m. EDT.
May 12, 2021 09:18 am ET
IIROC Trade Resumption - CRDL.WT.A
TORONTO, May 12, 2021 /CNW/ - Trading resumes in:
May 12, 2021 09:03 am ET
Cardiol Therapeutics Closes $22 Million Bought Deal Offering
Oakville, Ontario--(Newsfile Corp. - May 12, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce the closing of its previously announced "bought deal" short form prospectus offering (the "Offering") of units of the Company ("Units") for aggregate gross proceeds of approximately $22 million.
May 12, 2021 08:23 am ET
IIROC Trading Halt - CRDL.WT.A
TORONTO, May 12, 2021 /CNW/ - The following issues have been halted by IIROC:
May 06, 2021 09:11 am ET
Cardiol Announces Upsize to Previously Announced Bought Deal Public Offering
Cardiol Therapeutics Inc. (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce that, due to...
May 06, 2021 08:02 am ET
IIROC Trade Resumption - CRDL
TORONTO, May 6, 2021 /CNW/ - Trading resumes in:
May 05, 2021 04:44 pm ET
IIROC Trading Halt - CRDL
TORONTO, May 5, 2021 /CNW/ - The following issues have been halted by IIROC:
May 05, 2021 04:34 pm ET
Cardiol Therapeutics Announces $15 Million Bought Deal Public Offering
Cardiol Therapeutics Inc. (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce that it has...
Apr 28, 2021 06:07 am ET
Cardiol Therapeutics Announces First Patient Enrolled in LANCER, a Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with COVID-19
Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease
Apr 12, 2021 07:40 am ET
Cardiol Therapeutics Announces Topline Results from Phase I Single and Multiple Ascending Dose Clinical Trial of CardiolRx(TM)
Results expected to support the Company's plans to file an IND application with the FDA for a Phase II international trial in acute myocarditis
Apr 01, 2021 08:44 am ET
Cardiol Therapeutics Announces Filing of 2020 Year-End Financial Statements and MD&A
Oakville, Ontario--(Newsfile Corp. - April 1, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, today filed its audited Financial Statements and Management's Discussion and Analysis for the year ended December 31, 2020. Both are available under the Company's profile on SEDAR at www.sedar.com and on the Company's website at www.cardiolrx.com.
Mar 30, 2021 07:03 am ET
Cardiol Therapeutics Appoints Dr. Andrew Hamer as New Chief Medical Officer
Oakville, Ontario--(Newsfile Corp. - March 30, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, today announced that Dr. Andrew Hamer has joined the Company as Chief Medical Officer (CMO), effective immediately. Dr. Hamer will lead the research and development of the Company's clinical-stage products and will also guide the development of additional novel therapeutics in the Company's pipeline. Retiring CMO and co-founder of Cardiol, Dr. Eldon Smith, will continue to serve as Chair of the Board of Directors and as an advisor to the Company.
Mar 02, 2021 07:27 am ET
Cardiol Therapeutics Submits Application for Uplisting to the Nasdaq and Raises Proceeds of Over $10 Million from Exercise of Warrants and Options
Oakville, Ontario--(Newsfile Corp. - March 2, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, announced today that it has submitted an application to uplist the Company's common shares on The Nasdaq Capital Market® (the "Nasdaq") and that it has received proceeds of over $10 million from the exercise of warrants and stock options.
Feb 04, 2021 11:55 am ET
TMX Group, Cardiol Therapeutics, C-Suite at The Open
TORONTO, Feb. 4, 2021 /CNW/ - David Elsley, President & CEO, Cardiol Therapeutics Inc. (TSX: CRDL), shares his company's story in an interview with TMX Group.
Jan 21, 2021 07:27 am ET
Cardiol Therapeutics Announces Formation of Data Safety Monitoring and Clinical Endpoint Committees for Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with COVID-19
Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease
Jan 07, 2021 07:27 am ET
Cardiol Therapeutics to Participate in Upcoming Virtual Investor Conferences
Oakville, Ontario--(Newsfile Corp. - January 7, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory heart disease, announced today that David Elsley, President and CEO of Cardiol, will participate in the following upcoming virtual investor conferences:
Dec 22, 2020 07:27 am ET
Cardiol Therapeutics Announces Completion of Phase I Clinical Study of CardiolRx(TM)
Study results are expected to support the Company's plans to file an IND application with the FDA for a Phase II clinical trial in acute myocarditis
Dec 15, 2020 07:27 am ET
Cardiol Therapeutics Appoints Worldwide Clinical Trials as CRO for the Company's Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with COVID-19
Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease now being initiated at clinical centers in the United States
Oct 20, 2020 07:27 am ET
Cardiol Therapeutics' Cortalex(TM) CBD Now Available Exclusively Online at Medical Cannabis by Shoppers Inc.
The first pharmaceutically produced THC-free* extra-strength cannabidiol (CBD)
Sep 30, 2020 09:00 am ET
FDA Approves Landmark COVID/Heart/CBD Clinical Trial -- SECFilings.com
Redondo Beach, California--(Newsfile Corp. - September 30, 2020) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article covering a potentially major development in the quest to improve outcomes for COVID-19 patients. The US Food and Drug Administration (FDA) recently approved an Investigational New Drug application by Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) that opens the door for Cardiol to conduct its Phase II/III trial. The trial, designed by leading experts on inflammatory heart disease, will test the cardioprotective properties of cannabidiol (CBD) for COVID-19 patients with a prior history of, or risk factors for, cardiovascular disease (CVD).
Sep 25, 2020 07:55 am ET
IIROC Trade Resumption - CRDL
TORONTO, Sept. 25, 2020 /CNW/ - Trading resumes in:
Sep 25, 2020 06:03 am ET
Cardiol Therapeutics Receives FDA Approval for Investigational New Drug (IND) Application for Phase II/III COVID-19 Trial
Trial will take place at major U.S. centers and examine the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease (CVD)
Sep 24, 2020 10:11 am ET
IIROC Trading Halt - CRDL
TORONTO, Sept. 24, 2020 /CNW/ - The following issues have been halted by IIROC:
Sep 21, 2020 08:35 am ET
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
Life Sciences Investor Forum today announced that the presentations from the September 17th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased live company presentations and...
Sep 16, 2020 09:01 am ET
Cannabidiol Phase 1 Clinical Trial Launches, Targeting Inflammatory Heart Condition -- SECFilings.com
Redondo Beach, California--(Newsfile Corp. - September 16, 2020) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article covering Cardiol Therapeutics Inc.'s (TSX: CRDL) (OTCQX: CRTPF) initiation of a Phase 1 clinical study, intended to assess the safety, tolerability, and pharmacokinetics of its proprietary cannabidiol (CBD) formulation, CardiolRx™. The results of this study will inform Cardiol's planned Phase 2 international trial of CardiolRx™ for the treatment of acute myocarditis, an inflammatory heart condition. The phase 2 trial is being designed in conjunction with heart experts from leading medical centers in the U.S., Canada, and Germany. Rigorous clinical trials are the only way to drug approval, and Cardiol is hopeful that the abundance of laboratory evidence demonstrating CBD's anti-inflammatory properties translates into clinical proof of efficacy in treating acute myocarditis.
Sep 15, 2020 08:07 am ET
Cardiol Therapeutics to Present at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference
Oakville, Ontario--(Newsfile Corp. - September 15, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the development of pharmaceutical cannabidiol formulations for the treatment of cardiovascular diseases, including heart failure and acute myocarditis, announces that Cardiol's President and CEO, Mr. David Elsley, will present a company overview at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference today at 12:00 PM EDT.
Sep 14, 2020 08:35 am ET
Virtual Conference for Life Sciences Companies Broadcast Live September 17th, 2020
Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations and...
Aug 26, 2020 07:27 am ET
Cardiol Therapeutics Initiates Health Canada Approved Phase 1 Clinical Study of CardiolRx(TM)
Study Designed to Support Cardiol Therapeutics' Phase 2 International Trial in Acute Myocarditis
Aug 05, 2020 09:00 am ET
Orphan Drug Designation Is Proven Path for CBD -- SECFilings.com
Redondo Beach, California--(Newsfile Corp. - August 5, 2020) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article discussing how the past success of the orphan drug designation informs Cardiol Therapeutics Inc.'s (TSX: CRDL) (OTCQX: CRTPF) effort to develop CBD as a treatment for acute myocarditis. The Canadian-based company is utilizing pharmaceutical CBD in its research programs focused on various forms of heart failure and is preparing to launch its own brand of pharmaceutical CBD into the Canadian medical cannabis market
Jul 15, 2020 09:00 am ET
Heart Health and COVID-19: Fighting Inflammation May be Key -- SECFilings.com
Redondo Beach, California--(Newsfile Corp. - July 15, 2020) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article discussing the connection between heart disease, COVID-19, and inflammation. Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF), a pharmaceutical development company focused on heart health, is developing therapies to address the intertwined effects of these three conditions with the hope of improving outcomes for COVID-19 patients.
Jul 10, 2020 08:35 am ET
Cannabis & CBD Biopharma Investor Presentations Now Available for On-Demand Viewing
Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations
Jul 10, 2020 08:35 am ET
Cannabis & CBD Biopharma Investor Presentations Now Available for On-Demand Viewing
NEW YORK, July 10, 2020 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the Cannabis & CBD Biopharma Virtual lnvestor Conference presentations are now available for on-demand viewing.
Jul 07, 2020 03:00 pm ET
Live Investor Conference & Webinar: Cannabis & CBD Biopharma Industry Companies Present July 9th
Cannabis Company Executives share vision, answer questions live at VirtualInvestorConferences.com
Jul 07, 2020 03:00 pm ET
Live Investor Conference & Webinar: Cannabis & CBD Biopharma Industry Companies Present July 9th
NEW YORK, July 7, 2020 /PRNewswire/ -- Virtual Investor Conferences today announced the agenda for the upcoming Cannabis & CBD Industry Virtual Investor Conference. Individual investors, institutional investors, advisors and analysts are invited to attend. The program opens at 10:15 AM ET, with the first live webcast at 10:30 AM ET, on Thursday, July 9th.   
Jun 29, 2020 07:27 am ET
Cardiol Therapeutics Appoints CNBC Market Analyst Steven Grasso as Business Advisor
Oakville, Ontario--(Newsfile Corp. - June 29, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, is pleased to announce that it has appointed Steven Grasso as Business Advisor to the Company.
Jun 25, 2020 05:00 pm ET
David Elsley Files Early Warning Report for Cardiol Therapeutics
Oakville, Ontario--(Newsfile Corp. - June 25, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), today announced that David Elsley, President and CEO of Cardiol, has filed an early warning report (the "Report") in respect of his ownership of class A common shares of the Company (the "Shares") under the Company's profile on www.sedar.com as summarized below. This press release is being issued in accordance with National Instrument 62-103, referred to as The Early Warning System and Related Take-Over Bids and Insider Reporting Issues.
Jun 04, 2020 09:07 am ET
Cardiol Therapeutics Closes $17.25 Million Bought Deal Offering, Including Full Exercise of the Over-Allotment Option
Oakville, Ontario--(Newsfile Corp. - June 4, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, is pleased to announce the closing of its previously announced "bought deal" short form prospectus offering (the "Offering") of units of the Company ("Units") for aggregate gross proceeds of $17,250,000 which includes the full exercise of the over-allotment option.
Jun 02, 2020 03:45 pm ET
Cardiol Therapeutics Reports 2020 AGM Results
Oakville, Ontario--(Newsfile Corp. - June 2, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, announces results from its Annual General Meeting ("AGM") of shareholders held in Toronto, Ontario, on June 1, 2020. Shareholders voted in favour of all management resolutions proposed in the Company's Information Circular.
May 29, 2020 09:37 am ET
Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 1st at 4:30 p.m. EDT
Oakville, Ontario--(Newsfile Corp. - May 29, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, is pleased to announce that it will webcast the Company's virtual Annual General Meeting of Shareholders (the "AGM") on June 1, 2020, at 4:30 p.m. EDT.
May 14, 2020 09:43 am ET
Cardiol Therapeutics Announces Increase to Previously Announced Bought Deal Public Offering
Oakville, Ontario--(Newsfile Corp. - May 14, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, is pleased to announce that it has entered into an agreement with a syndicate of underwriters led by Canaccord Genuity Corp. (the "Underwriters") to increase the size of its previously announced bought deal financing. The Underwriters have agreed to purchase, on a bought deal basis pursuant to the filing of a short form prospectus, an aggregate of 6,000,000 units (the "Units") at a price of $2.50 per Unit (the "Offering Price") for aggregate gross proceeds to the Company of $15,000,000 (the "Offering").
May 13, 2020 05:44 pm ET
Cardiol Therapeutics Announces $11.25 Million Bought Deal Public Offering
Oakville, Ontario--(Newsfile Corp. - May 13, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. (the "Lead Underwriter") pursuant to which the Lead Underwriter has agreed, on behalf of a syndicate of underwriters (collectively, the "Underwriters"), to purchase, on a bought deal basis pursuant to the filing of a short form prospectus, an aggregate of 4,500,000 units (the "Units") at a price of $2.50 per Unit (the "Offering Price") for aggregate gross proceeds to the Company of $11,250,000 (the "Offering").
May 13, 2020 05:16 pm ET
Cardiol Therapeutics Announces $11.25 Million Bought Deal Public Offering
/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES NOR FOR DISSEMINATION IN THE UNITED STATES./
May 06, 2020 08:09 am ET
Cardiol Therapeutics Files International Patent Application Covering the Use of Cannabidiol (CBD) to Improve the Outcome of Patients with COVID-19
Oakville, Ontario--(Newsfile Corp. - May 6, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, is pleased to announce the filing of a new patent application covering the use of cannabidiol (CBD) to improve the outcome of patients with COVID-19. This new patent application includes the administration of CBD to reduce the severity of disease in COVID-19 patients with pre-existing cardiovascular conditions, and to prevent the progression of such conditions.
Apr 14, 2020 07:27 am ET
Cardiol Therapeutics Announces Study Demonstrating its Proprietary Nanotechnology Targets Fibrous Tissue in the Heart
Results showed a greater than 100-fold increase in uptake of Cardiol's nanoparticles in heart failure hearts compared with control hearts
Apr 01, 2020 07:27 am ET
Mar 26, 2020 06:03 pm ET
Cardiol Therapeutics Announces Filing of 2019 Year-End Financial Statements and MD&A
Oakville, Ontario--(Newsfile Corp. - March 26, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol medicines for heart disease, today filed its audited Year-end Financial Statements and Management's Discussion and Analysis for the year ended December 31, 2019. Both are available under the Company's profile on SEDAR at www.sedar.com and on the Company's website at www.cardiolrx.com.
Mar 18, 2020 07:27 am ET
Cardiol Therapeutics Signs Supplier Agreement with Medical Cannabis by Shoppers, a Subsidiary of Shoppers Drug Mart Inc.
Oakville, Ontario--(Newsfile Corp. - March 18, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart disease, is pleased to announce that it has signed a supplier agreement to offer its pharmaceutically produced cannabidiol to Medical Cannabis by Shoppers ("Shoppers"), a subsidiary of Shoppers Drug Mart Inc.
Mar 05, 2020 07:27 am ET
Cardiol Therapeutics Receives Health Canada Approval for Phase 1 Study of its Pharmaceutically Produced Cannabidiol (CBD) Formulation
Study represents the first Canadian clinical trial of an oral pharmaceutical cannabidiol product specifically formulated for patients who should not be exposed to THC
Jan 15, 2020 07:12 am ET
Cardiol Therapeutics' Exclusive Manufacturing Partner Receives Three-Year Renewal and Amendment of its Cannabis Act License from Health Canada
Oakville, Ontario--(Newsfile Corp. - January 15, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol medicines for heart disease, is pleased to announce that its exclusive manufacturing partner, Dalton Pharma Services ("Dalton"), has received a three-year renewal and license amendment of its Cannabis Act Processing License from Health Canada. This renewal and amendment will permit scaled commercial production of Cardiol's high concentration pharmaceutical cannabidiol formulations and their sale to other license holders.
Dec 18, 2019 07:47 am ET
Cardiol Therapeutics Appoints Michael J. Willner, Esq. as Business Advisor
Oakville, Ontario--(Newsfile Corp. - December 18, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol medicines for heart disease, is pleased to announce that it has appointed Michael J. Willner, Esq. as Business Advisor to the Company.
Dec 03, 2019 09:14 am ET
Cardiol Therapeutics Appoints Former GW Pharmaceuticals Executive Colin Stott to Its Board of Directors
Oakville, Ontario--(Newsfile Corp. - December 3, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol medicines for heart disease, is pleased to announce the appointment of Mr. Colin Stott to its Board of Directors, effective immediately. Mr. Stott is the former Scientific Affairs Director, International and R&D Operations Director for GW Pharmaceuticals plc ("GW Pharma"), a world leader in the development of cannabinoid therapeutics and the company which created Epidiolex®, the first FDA-approved cannabidiol therapy for use as an orphan drug in rare forms of pediatric epilepsy.
Nov 25, 2019 08:37 am ET
Cardiol Therapeutics Comments on the Descheduling of Purisys Cannabinoid Ingredients by U.S. Drug Enforcement Agency
Oakville, Ontario--(Newsfile Corp. - November 25, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol ("CBD") products and in the development of innovative cannabidiol medicines for heart disease, commented on Purisys, LLC's news release issued on November 21st which states that the U.S. Drug Enforcement Agency ("DEA") has removed their cannabinoid ingredients from Schedule I of the Controlled Substances Act ("CSA"). Purisys, LLC ("Purisys") is Cardiol's exclusive supplier of ultra-high purity cannabidiol for the Company's CardiolRx™ formulation. Pharmaceutically produced and cGMP certified, CardiolRx is designed to be the safest and most consistent cannabidiol formulation on the market.
Nov 19, 2019 07:02 am ET
Cardiol Therapeutics Announces Clinical Steering Committee for Phase 2 International Trial in Acute Myocarditis Using CardiolRx(TM) 100
Oakville, Ontario--(Newsfile Corp. - November 19, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) products and in the development of innovative cannabidiol medicines for heart disease, is pleased to announce the formation of the Clinical Steering Committee ("CSC") for a Phase 2 international trial in acute myocarditis using the Company's CardiolRx™100 cannabidiol formulation.
Oct 01, 2019 07:00 am ET
Cardiol Therapeutics Announces Completion of Manufacturing Scale-up for Commercialization of CardiolRx(TM)100
Oakville, Ontario--(Newsfile Corp. - October 1, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical CBD products and in the development of innovative CBD medicines for heart disease, announces that it has completed the manufacturing scale-up for commercialization of its CardiolRx™100 CBD formulation.
Sep 16, 2019 08:30 am ET
Cannabis Virtual Investor Conference Presentations Now Available for On-Demand Viewing
Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view the presentations
Sep 16, 2019 08:30 am ET
Cannabis Virtual Investor Conference Presentations Now Available for On-Demand Viewing
NEW YORK, Sept. 16, 2019 /PRNewswire/ -- Virtual Investor Conferences and KCSA Strategic Communications today announced that the presentations from the September 12th Cannabis Industry Virtual lnvestor Conference are now available for on-demand viewing at VirtualInvestorConferences.com.
Sep 11, 2019 08:35 am ET
/R E P E A T -- Live Investor Conference & Webinar: Cannabis Industry Companies Present September 12th/
Cannabis Company Executives share vision, answer questions live at VirtualInvestorConferences.com
Sep 06, 2019 09:15 am ET
Live Investor Conference & Webinar: Cannabis Industry Companies Present September 12th
NEW YORK, Sept. 6, 2019 /PRNewswire/ -- Virtual Investor Conferences and KCSA Strategic Communications today announced the agenda for the upcoming Cannabis Industry Virtual lnvestor Conference. Individual investors, institutional investors, advisors and analysts are invited to attend. The program opens at 9:15 AM ET, with the first live webcast at 9:30 AM ET, on Thursday, September 12th.
Sep 05, 2019 03:36 pm ET
Cardiol Therapeutics to Webcast Live at VirtualInvestorConferences.com on September 12th
Oakville, Ontario--(Newsfile Corp. - September 5, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in producing the purest pharmaceutical CBD products and developing innovative therapies for heart disease, today announced that David Elsley, President & Chief Executive Officer, will present live at the KCSA Cannabis Investor Conference at VirtualInvestorConferences.com on Thursday, September 12th.
Jul 25, 2019 09:53 am ET
Cardiol Therapeutics to Present at Canaccord Genuity 39th Annual Growth Conference
Oakville, Ontario--(Newsfile Corp. - July 25, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), focused on producing pharmaceutical CBD products and developing innovative therapies for heart disease, including acute myocarditis and other causes of heart failure, announces today that David Elsley, President and CEO of Cardiol, will be presenting at the Canaccord Genuity 39th Annual Growth Conference being held August 7-8, 2019 at the InterContinental Boston, MA. For two highly productive days, some of the best of the global growth universe will come together at the conference to share knowledge, discuss emerging trends, build relationships, identify opportunities, and ignite global ideas for growth. Cardiol's presentation is scheduled for August 8th at 11:30 a.m. EDT. The Company's management is also available for one-on-one meetings.
Jul 03, 2019 08:35 am ET
Grit Capital's Millennial Virtual Investor Conference Now Available for On-Demand Viewing
Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations
Jul 03, 2019 08:35 am ET
Grit Capital's Millennial Virtual Investor Conference Now Available for On-Demand Viewing
NEW YORK, July 3, 2019 /PRNewswire/ -- Virtual Investor Conferences, in partnership with Grit Capital, today announced that the presentations from our recent virtual event are now available for on-demand viewing. Eight public & private company executives provided insight on innovation, consolidation, international expansion and specialization in millennial investment industries. Login to now to watch the presentations and hear answers to questions from the audience.
Jun 21, 2019 12:50 pm ET
Grit Capital's Live-Stream Virtual Investor Conference June 26th
9 Company Executives of small cap millennial themed companies share their vision and answer questions live at VirtualInvestorConferences.com
Jun 20, 2019 09:06 am ET
Cardiol Therapeutics Announces Plans for Orphan Drug Program in Acute Myocarditis with CardiolRx CBD Formulation
Oakville, Ontario--(Newsfile Corp. - June 20, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical cannabidiol (CBD) and targeted therapies for heart disease, is pleased to announce that the Company is planning an international clinical trial in acute myocarditis utilizing its CardiolRx CBD formulation.
Jun 13, 2019 04:39 pm ET
Cardiol Therapeutics Reports Results of its AGM
Oakville, Ontario--(Newsfile Corp. - June 13, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical CBD and targeted therapies for heart disease, announces results from its Annual General Meeting ("AGM") of shareholders held in Toronto, Ontario, on June 12, 2019. Shareholders voted in favour of all management resolutions proposed in the Company's Information Circular.
Jun 10, 2019 11:03 am ET
Cardiol Therapeutics to Webcast Annual General Meeting on June 12
Oakville, Ontario--(Newsfile Corp. - June 10, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical CBD and targeted therapies for inflammatory diseases, is pleased to announce that it will be webcasting the informal portion of its annual general meeting (AGM) being held at Vantage Venues, 150 King Street West, 27th Floor, Toronto, on June 12, 2019, at 9:00 a.m. EDT.
Jun 06, 2019 08:35 am ET
Cannabis Virtual Investor Conference Presentations Now Available for On-Demand Viewing
Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view the presentations
Jun 03, 2019 08:03 am ET
May 31, 2019 08:35 am ET
Live Investor Conference & Webinar: Cannabis Industry Companies Present June 4th
Cannabis Company Executives share vision, answer questions live at VirtualInvestorConferences.com
May 30, 2019 08:33 am ET
Cardiol Therapeutics Commences Trading on the OTCQX
Oakville, Ontario--(Newsfile Corp. - May 30, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical CBD and targeted therapies for inflammatory diseases, is pleased to announce that it has qualified to trade on the OTCQX® Best Market and begins trading today under the symbol "CRTPF". U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the Company on www.otcmarkets.com.
May 07, 2019 09:00 am ET
Cardiol Therapeutics at the Intersection of Pharmaceutical CBD and Biotech, Plus Exclusive CEO Interview -- CFN Media
Seattle, Washington--(Newsfile Corp. - May 7, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry, announces the publication of an article and exclusive CEO video interview covering Cardiol Therapeutics Inc. (Cardiol) (TSX: CRDL) (OTC Pink: CRTPF), its development of cannabidiol (CBD) based drugs, and its plan to launch a commercial pharmaceutical CBD oil product.
Mar 28, 2019 08:47 am ET
Cardiol Therapeutics Announces Filing of Year-End Financial Statements and MD&A
Oakville, Ontario--(Newsfile Corp. - March 28, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a leader in the research and development of pharmaceutical cannabidiol and targeted therapies for inflammatory disease, today announced the filing of its audited year-end financial statements and management's discussion and analysis for the year ended December 31, 2018. Both are available under the Company's profile on SEDAR at www.sedar.com and on the Company's website at www.cardiolrx.com.
Mar 21, 2019 01:26 pm ET
The Science Behind Medical Marijuana is Flawed -- CFN Media
via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces the publication of an article discussing Cardiol Therapeutics (TSX: CRDL), a Canadian...
Mar 06, 2019 08:37 am ET
Cardiol Therapeutics Appoints Thomas Moffatt as Chief Commercial Officer
Oakville, Ontario--(Newsfile Corp. - March 6, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical cannabidiol products and targeted therapies for heart failure and cancer, is pleased to announce the appointment of Thomas (Tom) Moffatt, BBA, as Chief Commercial Officer.
Feb 20, 2019 09:00 am ET
Heart Failure and CBD -- CFN Media
via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering Cardiol Therapeutics (TSX: CRDL) (OTC: CRTPF) and its...
Jan 30, 2019 09:00 am ET
Cardiol Therapeutics Introducing Major Supply of Pharmaceutical CBD to Meet Supply Crunch -- CFN Media
Seattle, Washington--(Newsfile Corp. - January 30, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Cardiol Therapeutics' (TSX: CRDL) upcoming launch of its pharmaceutical CBD products, with the capacity to scale manufacturing to metric tonnes per year.
Jan 28, 2019 12:30 pm ET
Cardiol Therapeutics Inc. Closes the Market
TORONTO, Jan. 25, 2019 /CNW/ - David Elsley, President & CEO, Cardiol Therapeutics Inc. (CRDL), joined Loui Anastasopoulos, President, Capital Formation, Toronto Stock Exchange & TSX Venture Exchange, to close the market. Cardiol Therapeutics is a biotechnology company specializing in the research and commercial development of pharmaceutical cannabidiol products and targeted therapies for heart failure and cancer. Cardiol Therapeutics Inc. commenced trading on Toronto Stock Exchange on December 20, 2018.
Jan 18, 2019 09:14 am ET
Cardiol Therapeutics Inc. Closes Over-Allotment
Oakville, Ontario--(Newsfile Corp. - January 18, 2019) -  Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical cannabidiol products and targeted therapies for heart failure and cancer, announced today that the underwriters for the Company's initial public offering (the "Offering") have exercised their over-allotment option (the "Over-Allotment Option") to purchase an additional 374,544 Class A common shares of Cardiol (the "Optional Shares") at a price of $4.62 per Optional Share. The sale of the Optional Shares increases the gross proceeds of the Offering by $1,730,393, resulting in aggregate gross proceeds to Cardiol of $16,872,720.
Dec 20, 2018 09:27 am ET
Cardiol Therapeutics Completes Initial Public Offering and the Company's Common Shares and Warrants Commence Trading on the Toronto Stock Exchange Under the Symbols "CRDL" and "CRDL.WT"
Oakville, Ontario--(Newsfile Corp. - December 20, 2018) - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical cannabidiol products and targeted therapies for heart failure and cancer, announces that it has completed its initial public offering (the "IPO") on the Toronto Stock Exchange (the "TSX"). In connection with the IPO, Cardiol issued (a) 3,000,000 units (the "Units") at a price of $5.00 per Unit, with each Unit consisting of one Class A common share of the Company (a "Unit Share" and each Class A common share, a "Common Share") and one Common Share purchase warrant of the Company (a "Warrant"); and (b) an additional 374,544 Warrants at a price of $0.38 per Warrant pursuant to the partial exercise by the underwriters of the Over-Allotment Option, resulting in aggregate gross proceeds of $15,142,327. Cardiol's Common Shares will commence trading today on the TSX under the symbol "CRDL" and the Warrants will commence trading today under the symbol "CRDL.WT".
Dec 20, 2018 08:45 am ET
IIROC Trade Resumption - CRDL
TORONTO, Dec. 20, 2018 /CNW/ - Trading resumes in:
Dec 20, 2018 07:14 am ET
IIROC Trading Halt - CRDL
TORONTO, Dec. 20, 2018 /CNW/ - The following issues have been halted by IIROC: